Rifaximin Intramammary Infusion(Dry Cow)

Product Basic Information

Active Ingredient: Rifaximin

Specification: 5g:0.1g

(Each 5g pre-filled syringe contains 0.1g rifaximin )

Indications

This veterinary medicinal product is specifically indicated for dairy cows during the dry period (non-lactating phase) and is used for two core purposes targeting rifaximin-sensitive bacterial infections associated with bovine mastitis:

Treatment of existing mastitis:

For resolving clinical or subclinical mastitis caused by susceptible gram-positive bacteria, including Staphylococcus aureus (including some penicillin-resistant strains), coagulase-negative staphylococci (CNS), and Streptococcus species (e.g., Streptococcus agalactiae, Streptococcus dysgalactiae).

Prevention of new mastitis infections:

For reducing the risk of new mammary gland infections during the dry period, thereby minimizing the incidence of mastitis when cows transition to the subsequent lactation phase.

Dosage

The dosage is determined based on individual mammary quarters (not the entire cow) and must be administered under veterinary supervision, following strict aseptic procedures:

Per mammary quarter dose:

Administer 1 full syringe (5g formulation, equivalent to 0.1g rifaximin) per infected or at-risk mammary quarter.

Administration timing:

Administer once per mammary quarter, ideally within 24–48 hours after the last milking of the lactation cycle.

This timing ensures the udder is no longer actively lactating, allowing the medication to remain in the mammary gland and exert its antibacterial effect throughout the dry period.

Frequency:

administration per mammary quarter during the dry period.

Repeated doses are not recommended unless re-evaluated and instructed by a veterinarian .

Clinical Trial Data

Clinical efficacy of rifaximin intramammary infusion (5g:0.1g) in dry cows has been verified in multiple randomized controlled trials (RCTs) involving lactating dairy cows transitioning to the dry period.

Efficacy in Treating Pre-Existing Mastitis

Study Design:

A multi-farm RCT (n=186 dry cows with subclinical mastitis, confirmed by bacterial culture and elevated somatic cell count [SCC] >200,000 cells/mL). Cows were divided into two groups:

the treatment group (received rifaximin per infected quarter) and the control group (no antimicrobial treatment).

Key Results:

Bacterial clearance rate:

78.5% of infected quarters in the treatment group achieved bacterial clearance (negative bacterial culture) at 14 days post-administration, compared to only 22.3% in the control group.

SCC reduction: 

The treatment group showed a significant decrease in SCC (from baseline 380,000 ± 52,000 cells/mL to 110,000 ± 28,000 cells/mL) by the end of the dry period, while the control group had no significant SCC change.

Clinical mastitis resolution:

For cows with mild clinical mastitis (localized udder swelling, abnormal milk), 82.3% of treated quarters recovered (normal milk appearance, no swelling) within 7 days, versus 31.7% in the control group.

Efficacy in Preventing New Dry-Period Infections

Study Design:

A 6-month RCT (n=252 healthy dry cows, with all quarters culture-negative at dry-off). Cows were assigned to the prophylaxis group (all quarters received rifaximin) or the control group (no prophylaxis).

Key Results:

New infection rate:

The prophylaxis group had a new dry-period mastitis infection rate of 9.2% (per quarter), significantly lower than the control group’s 26.7%.

Lactation transition effect:

At the start of the next lactation, only 5.1% of quarters in the prophylaxis group had mastitis (clinical or subclinical), compared to 18.3% in the control group.

Target pathogen coverage:

The most common pathogens prevented were Staphylococcus aureus (91.3% reduction in new infections) and Streptococcus uberis (87.6% reduction), which are major causes of post-dry-off mastitis.

Storage: 2°C – 25°C (35.6°F – 77°F).

Package: 5g/syringe×20syringes/box×8boxes/carton